Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit Develops Prototype for Alzheimer's RNA-based Dx

NEW YORK (GenomeWeb News) - ExonHit said yesterday that it has developed a prototype for a blood-based diagnostic to identify patients suffering from Alzheimer’s disease.
 
The company said the test is based on hybridizing RNA isolated from blood on an Affymetrix microarray, and it can distinguish patients suffering from Alzheimer’s disease from those suffering from schizophrenia, bipolar disorders, and depression.
 
The test is designed to identify Alzheimer’s sufferers, but the company said it is assessing the feasibility of using it to identify patients suffering from mild cognitive impairment who are at risk to develop Alzheimer-type dementia.
 
ExonHit’s executive VP for research, Laurent Bracco, said the company is “confident that the test will also be able to screen out patients suffering from other dementias such as frontal lobe dementias, Lewy body dementias, or vascular dementias.”
 
ExonHit said it expects it will have the test certified and ready to market to pharmaceutical companies as early as 2009.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.